GlassScriptPhysician profile
Muhammad W Sajid
NPI 1801825500
$4,650.42
in general payments reported to CMS, 2019-2025
27 companies · $576 in 2025
The $576 reported for 2025 was more than what 78% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $1,081 · 2021: $252 · 2022: $675 · 2023: $589 · 2024: $965 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,000.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $736.99 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Supernus Pharmaceuticals, INC. | $477.83 | 2022-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $475.99 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $250.52 | 2019-2025 | Spravato |
| Corium, LLC | $219.69 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $218.25 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $174.42 | 2019-2025 | Rexulti |
| Neuronetics, INC. | $155.99 | 2020-2025 | Neurostar Tms Therapy System |
| Alkermes, INC. | $146.60 | 2022-2024 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $134.93 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $123.95 | 2019-2020 | |
| Abbvie INC. | $80.28 | 2022-2023 | Vraylar |
| Lundbeck LLC | $66.74 | 2019-2025 | Abilify Maintena, Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $62.77 | 2024-2025 | Rejoyn |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.40 | 2021-2023 | Caplyta |
| Tris Pharma INC | $43.01 | 2023-2024 | Dyanavel Xr |
| Indivior INC. | $37.20 | 2023-2024 | Perseris |
| Uswm, LLC | $33.46 | 2023 | Lucemyra, Zimhi |
| Noven Therapeutics, LLC | $31.85 | 2024-2025 | Xelstrym |
| Bausch Health US, LLC | $23.65 | 2022 | |
| Neurocrine Biosciences, INC. | $22.24 | 2025 | |
| Axsome Therapeutics, INC. | $16.94 | 2025 | Auvelity |
| Allergan, INC. | $16.48 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.18 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Sajid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.